Clinical Trial

Letermovir for R+ Study

Name: Letermovir for R+ Study — clinical trial record (NCT07706166)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MISP CMV

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.

Trial Details

NCT Number	NCT07706166
Lead Sponsor	University of Wisconsin, Madison Collaborators: Merck Sharp & Dohme LLC
Conditions	Kidney Transplant, Liver Transplant
Enrollment	146 participants
Start Date	2026-08
Primary Completion	2029-08 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-15